Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
See our latest analysis for Amicus Therapeutics. That sharp 45.57% 30 day share price return and 72.05% 90 day share price return to around $14.28 comes after a far more muted year to date share price move and a 50.95% 1 year total shareholder return. Momentum currently appears to be building off a previously softer multi year picture that includes an 11.13% 3 year and 38.69% 5 year total shareholder return. If Amicus has you looking across rare disease and biotech names, this could be a useful moment to scan other healthcare stocks that may fit a similar thesis or diversify it. With the shares now close to the average analyst price target and an internal model implying a wide intrinsic discount, the key question is whether Amicus still trades below its true worth or whether the market is already pricing in future growth. The most followed narrative puts Amicus Therapeutics' fair value at US$14.80, only slightly above the last close of US$14.28, suggesting limited room betwee
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential [Yahoo! Finance]Yahoo! Finance
- Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.MarketBeat
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock.MarketBeat
- Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLDBusiness Wire
FOLD
Earnings
- 11/4/25 - Beat
FOLD
Sec Filings
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- FOLD's page on the SEC website